Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back program, with a total of 3,293,119 securities bought back before the previous day and an additional 23,382 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is primarily engaged in creating treatments that address unmet needs in the market for neurological health.
Average Trading Volume: 766,565
Technical Sentiment Signal: Hold
Current Market Cap: A$1.53B
See more data about NEU stock on TipRanks’ Stock Analysis page.